Genetic variants in ABCC3, ABCC5, FasL, GLDC and GSTP1 were repeatedly associated to osteosarcoma treatment outcome, using very heterogeneous efficacy outcomes. This evidence concerns the gene ABCC5 and osteosarcoma.